Lisa B. Leypoldt

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Real-world analyses of bispecific antibodies and CAR-T cell therapy in relapsed or refractory multiple myeloma: a global TriNetX discovery and contemporary validation cohort.

Journal: Leukemia & lymphoma

Published: July 28, 2026

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience.

Adaptive bridging and holding therapy frequently reduces tumor burden and is associated with reduced toxicity after CAR-T cell therapy in multiple myeloma: A single-center real-world experience.

Journal: Transplantation and cellular therapy

Published: June 21, 2026

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 08, 2026

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 21, 2026

A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma.

A structural framework for mutation-guided immunotherapy sequencing of GPRC5D-targeted T cell engagers in multiple myeloma.

Journal: Blood cancer journal

Published: April 27, 2026

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis.

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis.

Journal: Annals of hematology

Published: February 18, 2026

Precision Oncology in Northern Germany - Integrating Multi-Omics and AI to Support Evidence-Based Molecular Tumor Boards.

Precision Oncology in Northern Germany - Integrating Multi-Omics and AI to Support Evidence-Based Molecular Tumor Boards.

Journal: Oncology research and treatment

Published: February 04, 2026

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.

Journal: Leukemia

Published: December 06, 2025

How to approach the high-risk myeloma from induction through relapse?

How to approach the high-risk myeloma from induction through relapse?

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

Journal: American journal of hematology

Published: December 02, 2025

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.

Journal: Blood cancer journal

Published: November 01, 2025

Understanding quality of life under talquetamab: Learning to measure what matters.

Understanding quality of life under talquetamab: Learning to measure what matters.

Journal: Cancer

Published: August 26, 2025

Showing 1-12 of 35

Last Updated: 09/26/2026